A Phase III, Randomised, Double-blind, Placebo-controlled, Parallel-group Trial to Evaluate Efficacy and Safety of Tiotropium Inhalation Solution Delivered Via Respimat Inhaler (2.5ug and 5ug Once Daily) Compared to Placebo Over 12 Weeks in Mild Persistent Asthma.

Trial Profile

A Phase III, Randomised, Double-blind, Placebo-controlled, Parallel-group Trial to Evaluate Efficacy and Safety of Tiotropium Inhalation Solution Delivered Via Respimat Inhaler (2.5ug and 5ug Once Daily) Compared to Placebo Over 12 Weeks in Mild Persistent Asthma.

Completed
Phase of Trial: Phase III

Latest Information Update: 24 May 2017

At a glance

  • Drugs Tiotropium bromide (Primary)
  • Indications Asthma
  • Focus Registrational; Therapeutic Use
  • Acronyms GraziaTinA-asthma
  • Sponsors Boehringer Ingelheim Pharmaceuticals
  • Most Recent Events

    • 24 May 2017 Results of clinical outcome data from five phase III studies (GraziaTinA-asthma, MezzoTinA-asthma-1, MezzoTinA-asthma-2, RubaTinA-asthma and PensieTinA-asthma) presented at the 113th International Conference of the American Thoracic Society
    • 24 May 2017 Results of subgroup analysis of five phase III studies presented at the 113th International Conference of the American Thoracic Society.
    • 24 May 2017 Results of pooled data analysis of 10 phase III studies (NinoTinA-asthma, CanoTinA-asthma,VivaTinA-asthma, RubaTinA-asthma,PensieTinA-asthma,GraziaTinA-asthma,MezzoTinA-asthma,PrimoTinA-asthma) assessing safety and tolerability presented at the 113th International Conference of the American Thoracic Society.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top